CAMBRIDGE, MA / ACCESS Newswire / May 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and ...
The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential pandemic influenza viruses, including the H5N1 bird flu. The company said it ...
A Washington resident has been hospitalized with bird flu, according to the Washington State Health Department, and they’re ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback